We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Organon (OGN - Free Report) was up +1.23% at $9.05. The stock's performance was ahead of the S&P 500's daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.89%.
Prior to today's trading, shares of the pharmaceutical company had lost 14.12% lagged the Medical sector's gain of 3.7% and the S&P 500's gain of 0.16%.
The upcoming earnings release of Organon will be of great interest to investors. On that day, Organon is projected to report earnings of $0.93 per share, which would represent year-over-year growth of 6.9%. At the same time, our most recent consensus estimate is projecting a revenue of $1.57 billion, reflecting a 0.74% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.84 per share and revenue of $6.3 billion, indicating changes of -6.57% and -1.55%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.96% higher. At present, Organon boasts a Zacks Rank of #3 (Hold).
Investors should also note Organon's current valuation metrics, including its Forward P/E ratio of 2.33. Its industry sports an average Forward P/E of 17.11, so one might conclude that Organon is trading at a discount comparatively.
It's also important to note that OGN currently trades at a PEG ratio of 0.77. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services was holding an average PEG ratio of 1.72 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Laps the Stock Market: Here's Why
In the latest close session, Organon (OGN - Free Report) was up +1.23% at $9.05. The stock's performance was ahead of the S&P 500's daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.89%.
Prior to today's trading, shares of the pharmaceutical company had lost 14.12% lagged the Medical sector's gain of 3.7% and the S&P 500's gain of 0.16%.
The upcoming earnings release of Organon will be of great interest to investors. On that day, Organon is projected to report earnings of $0.93 per share, which would represent year-over-year growth of 6.9%. At the same time, our most recent consensus estimate is projecting a revenue of $1.57 billion, reflecting a 0.74% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.84 per share and revenue of $6.3 billion, indicating changes of -6.57% and -1.55%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.96% higher. At present, Organon boasts a Zacks Rank of #3 (Hold).
Investors should also note Organon's current valuation metrics, including its Forward P/E ratio of 2.33. Its industry sports an average Forward P/E of 17.11, so one might conclude that Organon is trading at a discount comparatively.
It's also important to note that OGN currently trades at a PEG ratio of 0.77. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services was holding an average PEG ratio of 1.72 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.